Aug. 19 at 3:07 PM
$LSTA Agreed w/ post below @Biotech_Pharma_Investor! As confirmed by Kuva CEO yesterday via email they are still actively working on putting together a fully funded offer. This option is not dead yet, but even if it is and RM is the solution, we are still in a safe zone imo.
10Q shows 10m cash end of June 30, 2026. 1.2m in costs with workforce reduction, and burn of 3-4m in GA expenses puts this at 5m cash end of Sept 30, 2026. Likely has 7m in cash today + NASDAQ shell worth 7-10m.
In an RM scenario the likely value would be 3m cash + NASDAQ shell = 10m or 1.10/share FLOOR valuation, giving ZERO value to assets. The math still supports the current PPS imo
If anyone needs convincing, take a look at
$PCSA which had negative cash (weeks away from BK) and just completed a RM transaction and is trading at 6m mc. NASDAQ shells have a lot more value than people like to admit!
